Royalty Pharma (RPRX) announced the appointment of Carole Ho and Elizabeth Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics (DNLI). Bess Weatherman is a Special Limited Partner of Warburg Pincus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma price target raised to $54 from $51 at Morgan Stanley
- Strategic Financial Agreements and Promising Drug Developments Justify Buy Rating for Royalty Pharma
- Royalty Pharma’s Strategic Partnership with Revolution Medicines: A High-Reward Investment Opportunity
- Royalty Pharma announces $2B funding arrangement with Revolution Medicines
- Revolution Medicines enters $2B funding agreement with Royalty Pharma